Education
About Us
Working with TipRanks
Follow Us
Portage Biotech Inc (PRTG)
NASDAQ:PRTG
PRTG Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.42 - $23.01
Previous CloseN/A
Volume13.74K
Average Volume (3M)37.94K
Market Cap
$18.23M
Enterprise Value$4.72M
Total Cash (Recent Filing)$1.76M
Total Debt (Recent Filing)$28.00K
Price to Earnings (P/E)―
Beta2.01
Next Earnings
Sep 01, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,278,622
10 Day Avg. Volume47,539
30 Day Avg. Volume37,935
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-131.01
Enterprise Value/Ebitda-0.06
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Portage Biotech Inc News
PRTG FAQ
What was Portage Biotech Inc’s price range in the past 12 months?
Portage Biotech Inc lowest stock price was $2.42 and its highest was $23.01 in the past 12 months.
What is Portage Biotech Inc’s market cap?
Portage Biotech Inc’s market cap is $18.23M.
When is Portage Biotech Inc’s upcoming earnings report date?
Portage Biotech Inc’s upcoming earnings report date is Sep 01, 2025 which is in 9 days.
How were Portage Biotech Inc’s earnings last quarter?
Currently, no data Available
Is Portage Biotech Inc overvalued?
According to Wall Street analysts Portage Biotech Inc’s price is currently Overvalued.
Does Portage Biotech Inc pay dividends?
Portage Biotech Inc does not currently pay dividends.
What is Portage Biotech Inc’s EPS estimate?
Portage Biotech Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Portage Biotech Inc have?
Portage Biotech Inc has 2,278,622 shares outstanding.
What happened to Portage Biotech Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Portage Biotech Inc?
Currently, no hedge funds are holding shares in PRTG
Company Description
Portage Biotech Inc
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Technical Analysis
Can-Fite BioPharma
―
Phio Pharmaceuticals
―
Cellectar Biosciences
―
MetaVia
―
Bolt Biotherapeutics
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
0.85% Other Institutional Investors
99.15% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---